ImClone, Round 2: One Hit, One Miss
A House panel's second hearing on the biotech turns up new dirt on CEO Waksal -- but makes little progress toward FDA reforms
By Catherine Arnst
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: